A trial for the world’s first-ever mRNA cancer vaccine for melanoma is underway in the UK. Melanoma is the deadliest form of skin cancer. Around 100,000 Americans are expected to be diagnosed with ...

GRAND RAPIDS, Mich — There could be a new vaccine to prevent cancer. Companies Moderna and Merck said their clinical trials of a melanoma vaccine, combined with immunotherapy Keytruda, are lowering ...

The new melanoma vaccine significantly improves long-term survival rates compared to previous versions, with notable benefits in male patients. The vaccine uses stable peptide fragments to stimulate ...

An experimental skin cancer vaccine developed by pharmaceutical companies Moderna and Merck shows promising results after a five-year follow-up in clinical trials. The findings point to strong, ...

A second-generation melanoma vaccine being developed at UVA Cancer Center improves long-term survival for melanoma patients compared with the first-generation vaccine, new research shows.

May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...

Skin cancer patients are set to be fast-tracked into a clinical trial for a new cancer vaccine, NHS England has announced. The vaccine, called iSCIB1+, is designed to help the immune system better ...

Researchers are recruiting some 1,100 people globally to participate in the trial's third phase. Ivan Radic via Flickr CC BY 2.0 DEED A global trial has begun for the world’s first personalized ...

Melanoma, the most dangerous type of skin cancer, remains in the top five cancers diagnosed in both men and women. Scientists understand that most melanoma cells express antigens, proteins that prompt ...

The groundbreaking development of the world's first skin cancer vaccine represents a significant leap forward in medical innovation. As this personalized mRNA vaccine enters its final trial phase, it ...

A second-generation melanoma vaccine being developed at UVA Cancer Center improves long-term survival for melanoma patients compared with the first-generation vaccine, new research shows.

Results from human trials coupling a new melanoma vaccine with an existing cancer drug showed that, at the three-year mark, the combination treatment reduced the risk of melanoma recurring by 49% and ...